Compare Stocks: CUBTD, QNCX, CVM, and KYNB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUBTD Curative Biotechnology	$1.10	$1.10	$0.03 ▼ $2.24	$7.50M	1.31	2,679 shs	N/A
CVM Cel-Sci	$1.66 +11.4%	$1.43	$0.89 ▼ $10.83	$29.01M	0.61	108,621 shs	264,960 shs
KYNB Kyntra Bio	$7.07 -0.4%	$7.45	$6.32 ▼ $12.58	$28.65M	1.06	23,374 shs	79,868 shs
QNCX Quince Therapeutics	$29.48 +9.1%	$27.43	$15.10 ▼ $909.98	$29.98M	1.31	17,690 shs	48,834 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUBTD Curative Biotechnology	0.00%	0.00%	0.00%	0.00%	-2.22%
CVM Cel-Sci	0.00%	+11.41%	+13.70%	+59.62%	-81.20%
KYNB Kyntra Bio	0.00%	-11.29%	-3.42%	+5.52%	+706,999,900.00%
QNCX Quince Therapeutics	0.00%	-0.24%	-8.19%	+55.96%	-90.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUBTD Curative Biotechnology	$1.10	$1.10	$0.03 ▼ $2.24	$7.50M	1.31	2,679 shs	N/A
CVM Cel-Sci	$1.66 +11.4%	$1.43	$0.89 ▼ $10.83	$29.01M	0.61	108,621 shs	264,960 shs
KYNB Kyntra Bio	$7.07 -0.4%	$7.45	$6.32 ▼ $12.58	$28.65M	1.06	23,374 shs	79,868 shs
QNCX Quince Therapeutics	$29.48 +9.1%	$27.43	$15.10 ▼ $909.98	$29.98M	1.31	17,690 shs	48,834 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUBTD Curative Biotechnology	0.00%	0.00%	0.00%	0.00%	-2.22%
CVM Cel-Sci	0.00%	+11.41%	+13.70%	+59.62%	-81.20%
KYNB Kyntra Bio	0.00%	-11.29%	-3.42%	+5.52%	+706,999,900.00%
QNCX Quince Therapeutics	0.00%	-0.24%	-8.19%	+55.96%	-90.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUBTD Curative Biotechnology	0.00	N/A	N/A	N/A
CVM Cel-Sci	0.00	N/A	N/A	N/A
KYNB Kyntra Bio	2.67	Moderate Buy	$37.25	426.87% Upside
QNCX Quince Therapeutics	2.42	Hold	$260.00	781.95% Upside

Current Analyst Ratings Breakdown

Latest CUBTD, QNCX, CVM, and KYNB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	KYNB Kyntra Bio	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$41.00
9/17/2026	KYNB Kyntra Bio	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/1/2026	KYNB Kyntra Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$43.00
8/27/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/26/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$68.00
8/18/2026	QNCX Quince Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$70.00
8/14/2026	KYNB Kyntra Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/12/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/29/2026	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$82.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUBTD Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A
CVM Cel-Sci	N/A	N/A	N/A	N/A	$2.32 per share	N/A
KYNB Kyntra Bio	$6.44M	4.45	N/A	N/A	($4.20) per share	-1.68
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUBTD Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CVM Cel-Sci	-$25.41M	-$9.77	N/A	N/A	N/A	N/A	-250.83%	-125.06%	N/A
KYNB Kyntra Bio	$183.45M	$45.30	0.16	N/A	N/A	2,199.13%	N/A	-47.27%	N/A
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-133.84%	11/11/2026 (Estimated)

Latest CUBTD, QNCX, CVM, and KYNB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q3 2026	CVM Cel-Sci	N/A	-$0.47	N/A	-$0.47	N/A	N/A
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUBTD Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
CVM Cel-Sci	N/A	N/A	N/A	N/A	N/A
KYNB Kyntra Bio	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUBTD Curative Biotechnology	N/A	N/A	N/A
CVM Cel-Sci	0.35	1.48	1.42
KYNB Kyntra Bio	N/A	2.69	2.59
QNCX Quince Therapeutics	N/A	14.52	14.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUBTD Curative Biotechnology	N/A
CVM Cel-Sci	12.08%
KYNB Kyntra Bio	72.71%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
CUBTD Curative Biotechnology	N/A
CVM Cel-Sci	9.93%
KYNB Kyntra Bio	4.15%
QNCX Quince Therapeutics	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUBTD Curative Biotechnology	4	6.82 million	N/A	Not Optionable
CVM Cel-Sci	44	17.48 million	15.74 million	No Data
KYNB Kyntra Bio	570	4.05 million	3.88 million	N/A
QNCX Quince Therapeutics	38	1.02 million	960,000	Optionable

CUBTD, QNCX, CVM, and KYNB Headlines

Recent News About These Companies

Quince Therapeutics (NASDAQ:QNCX) Shares Up 9.1% - Should You Buy?

September 20 at 6:40 AM | americanbankingnews.com

Quince Therapeutics stock prepares for LAM-001 KOL event as shares trade below recent highs

September 19 at 8:05 AM | ad-hoc-news.deA

Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Hold" from Brokerages

September 19 at 4:29 AM | americanbankingnews.com

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on ...

September 17 at 8:28 AM | finance.yahoo.com

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

September 17 at 8:00 AM | globenewswire.com

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026 | quiverquant.comQ

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026 | globenewswire.com

Quince Therapeutics Announces Planned Presidential Leadership Transition

August 27, 2026 | tipranks.com

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

August 14, 2026 | globenewswire.com

Quince Therapeutics

July 6, 2026 | fool.com

Quince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | Benzinga

July 2, 2026 | benzinga.com

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

June 30, 2026 | globenewswire.com

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

June 11, 2026 | seekingalpha.com

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy

June 2, 2026 | insidermonkey.com

Quince Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk

May 24, 2026 | theglobeandmail.com

Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript

May 18, 2026 | seekingalpha.com

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

May 18, 2026 | globenewswire.com

Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60

May 15, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUBTD, QNCX, CVM, and KYNB Company Descriptions

Curative Biotechnology OTCMKTS:CUBTD

$1.10 0.00 (0.00%)

As of 09/18/2026

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

Cel-Sci NYSEAMERICAN:CVM

$1.66 +0.17 (+11.41%)

Closing price 09/18/2026 04:10 PM Eastern

Extended Trading

$1.65 -0.01 (-0.54%)

As of 09/18/2026 07:57 PM Eastern

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Kyntra Bio NASDAQ:KYNB

$7.07 -0.03 (-0.42%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.10 +0.03 (+0.42%)

As of 09/18/2026 07:30 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Quince Therapeutics NASDAQ:QNCX

$29.48 +2.47 (+9.14%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$29.49 +0.01 (+0.03%)

As of 09/18/2026 07:55 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CUBTD, QNCX, CVM, and KYNB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CUBTD, QNCX, CVM, and KYNB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CUBTD, QNCX, CVM, and KYNB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUBTD, QNCX, CVM, and KYNB Company Descriptions

Curative Biotechnology OTCMKTS:CUBTD

Cel-Sci NYSEAMERICAN:CVM

Kyntra Bio NASDAQ:KYNB

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CUBTD, QNCX, CVM, and KYNB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CUBTD, QNCX, CVM, and KYNB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CUBTD, QNCX, CVM, and KYNB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUBTD, QNCX, CVM, and KYNB Company Descriptions

Curative Biotechnology OTCMKTS:CUBTD

Cel-Sci NYSEAMERICAN:CVM

Kyntra Bio NASDAQ:KYNB

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools